Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 6,700 shares of common stock at $24.58 per share. According to the filing, these shares were automatically sold to cover tax withholding obligations tied to vesting of restricted stock units under Beam’s 2019 Equity Incentive Plan and were executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Simon directly holds 102,735 Beam shares, and the total includes shares acquired through the company’s Employee Stock Purchase Plan.
Beam Therapeutics SVP Finance Bethany J. Cavanagh reported an automatic sale of common stock mainly to cover taxes on vesting equity awards. On April 1, 2026, 3,242 shares were sold in an open-market transaction at $24.58 per share. These shares were sold to satisfy tax withholding obligations tied to restricted stock units granted under the company’s 2019 Equity Incentive Plan that vested on multiple March 31 dates from 2022 through 2025. Following the sale, Cavanagh directly holds 51,171 Beam Therapeutics shares. The filing notes the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 9, 2024, indicating the timing was set in advance rather than chosen opportunistically.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported an automatic sale of 5,956 shares of common stock on April 1, 2026 at $24.58 per share. After this transaction, she directly holds 109,711 shares of Beam Therapeutics common stock.
The shares were sold in a non-discretionary transaction solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on March 31 of 2022, 2023, 2024 and 2025 under the company’s 2019 Equity Incentive Plan. The sales were effected under a Rule 10b5-1 trading plan adopted on May 19, 2023, indicating the trades were pre-planned rather than opportunistic market sales.
Beam Therapeutics President Giuseppe Ciaramella reported an automatic sale of 11,810 shares of common stock at $24.58 per share. The shares were sold to cover tax withholding obligations tied to previously granted restricted stock units and executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, he directly holds 218,406 shares of Beam Therapeutics common stock.
Bellon Christine reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that Chief Legal Officer Christine Bellon received a grant of 20,000 restricted stock units (RSUs) of common stock on March 31, 2026. Each RSU equals one share and was granted at no cash cost to her.
The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the grant date, conditioned on her continued service with Beam. After this award, she holds 115,667 shares of Beam common stock directly, reflecting a routine, compensation-related equity grant rather than an open-market purchase.
Cavanagh Bethany J reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that SVP, Finance and Treasurer Bethany J. Cavanagh received a grant of 20,000 restricted stock units under the company’s 2019 Equity Incentive Plan. Each RSU represents one share of common stock and vests in four equal annual installments, subject to continued service. Following this award, she holds 54,813 shares directly.
Simon Amy reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. granted Chief Medical Officer Amy Simon 31,750 restricted stock units (RSUs), each representing the right to receive one share of Beam common stock. The RSUs vest in four substantially equal annual installments on the first four anniversaries of the grant date, conditioned on her continued service. Following this award, she directly holds 109,114 shares of Beam common stock, reflecting a compensation-related equity grant rather than an open-market transaction.
Emany Sravan Kumar reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that its Chief Financial Officer, Sravan Kumar Emany, received a grant of 31,750 shares of common stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in four substantially equal annual installments, starting on the first anniversary of the grant date, if he continues serving at the company. Following this award, his directly held common stock position is 105,456 shares, reflecting compensation tied to long-term service and company performance.
Ciaramella Giuseppe reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that President Giuseppe Ciaramella received an equity grant of 40,000 restricted stock units (RSUs) of common stock. Each RSU represents the right to receive one Beam share and will vest in four substantially equal annual installments, subject to his continued service. Following this award, he directly holds 230,216 shares of Beam common stock, including the RSUs.
Beam Therapeutics CEO John M. Evans reported multiple equity transactions in Beam Therapeutics Inc. stock. He exercised stock options for 50,000 shares of common stock at an exercise price of $0.67 per share, then sold 50,000 shares in open-market transactions at weighted average prices of $22.3692 and $22.7634 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on May 16, 2025. Evans also received 90,000 restricted stock units under the Beam 2019 Equity Incentive Plan, vesting in four equal annual installments, and now holds 986,667 shares directly and 103,000 shares indirectly through a trust.